Patent · US Active

Isoform-selective TGFB1 inhibitors and use thereof

US12122823B2 · kind B2 · utility

0Cited by

7References

13Claims

0Family size

Assignee

Scholar Rock, Inc. · US

Inventors

Abhishek Datta · Boston, US
Allan Capili · Somerville, US
Thomas Schurpf · Cambridge, US
Constance Martin · Arlington, US
Kevin B. Dagbay · Watertown, US
Christopher Chapron · Watertown, US
Stefan Wawersik · Westborough, US
Christopher Littlefield · Marblehead, US
Gregory J. Carven · Maynard, US
Alan Buckler · Irvine, US
Susan S. Lin · Kirkland, US
Justin W. Jackson · Cambridge, US
Caitlin Stein · Clarkston, US
Matthew Salotto · Hanover, US
Andrew Avery · Lebanon, US
Anthony William James Cooper · Stevenage, GB

Key dates

Filing date	Aug 19, 2021
Grant date	Oct 22, 2024
Priority date	—
Expiry date	Feb 16, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.